Exhibit 99.02


     The Company incurred special items during the third quarter of fiscal 2005
consisting primarily of restructuring charges of $25.8 million, merger-related
charges of $10.4 million and costs related to the SEC investigation and Audit
Committee internal review of $7.1 million. Restructuring charges primarily
relate to the previously announced global restructuring program. The costs
incurred to date under the global restructuring program primarily consist of
employee-related costs, asset impairments and facility exit costs.
Merger-related charges include such items as employee-related costs and costs
associated with exit and consolidation of facilities, as well as costs of
integrating acquired businesses. Costs related to the SEC investigation and
Audit Committee internal review primarily include legal fees and document
preservation and production costs. On an after-tax basis, the special items
incurred during the third quarter of fiscal 2005 totaled $28.5 million versus
$4.9 million for the year-earlier period. In the opinion of management, these
special items, by their nature, rarely have predictable trends and are not truly
reflective of ongoing operating results. Therefore, the Company presents its
results on both a generally accepted accounting principles basis ("GAAP") and a
GAAP basis excluding these special items ("adjusted").

     Management uses adjusted results to measure its performance in addition to
the GAAP results. As the Company's core business is providing health care
products and services to the health care industry, management finds it useful to
use a metric that does not include charges and gains associated with
restructuring, merger-related activity and litigation. While these special items
may be recurring items for the Company, management believes they are not
reflective of the day-to-day offering of its products and services and relate
more to strategic, multi-year corporate actions that tend to mask the trends and
financial performance of the Company's products and services. Management
believes that investors may also find an unmasked view of the Company's core
operations to be useful.

     In addition, the Company has identified certain items that are either
infrequent or will aid the reader in analyzing comparability between prior
periods. These items include asset impairment charges and losses on the sale of
fixed assets of $16.2 million as well as an inventory write-off adjustment of
$7.2 million related to an SKU rationalization project within the Company's
Pharmaceutical Distribution business. The Company provided information regarding
the impact of each of these items on its consolidated results. The Company
believes this information is useful for investors' assessment of the operating
trends of the Company's businesses.

     Management encourages readers to rely upon the GAAP numbers, but includes
the GAAP amounts that have been adjusted as a supplemental metric to assist
readers. It should be noted that the items being adjusted from the GAAP results
represent actual income or expense to the Company. These items impact operating
cash flow available to support on-going operations. As such, these items are an
important component of the financial performance of the Company and any metric
excluding them will present an incomplete picture.